Agonists of α7 nAChR are considered promising compounds for the treatment of AD and have been shown to lower Aβ deposition and to reverse long-term potentiation deficits induced by synaptotoxic Aβ oligomers [53–56]. Here, CHRNA7 is linked to Alzheimer disease.